Science Explorer Interactive view Map
Company · Tromsø · Norway

Biotec Pharmacon (Norway)

Research works
4
▼ 100% vs 2013–17
Citations
169
41.4 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
47%
world 28%

Not ranked overall: Biotec Pharmacon (Norway) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which research topics does Biotec Pharmacon (Norway) publish most on?

By volume in 2022–2025: Antibiotics Pharmacokinetics and Efficacy, Antibiotic Resistance in Bacteria and Pneumocystis jirovecii pneumonia detection and treatment.

  1. 1 Antibiotics Pharmacokinetics and Efficacy Pharmacology 0 works
  2. 2 Antibiotic Resistance in Bacteria Molecular Medicine 0 works
  3. 3 Pneumocystis jirovecii pneumonia detection and treatment Epidemiology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available46.9%not open53.1%

World: 28% of research is openly available.

with international co-authors22.4%domestic only77.6%

World: 19% is written across borders.

How has Biotec Pharmacon (Norway)'s research output changed?

Output in 2018–2022 was 100% lower than in 2013–2017.

20052010
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Tromsø

All research institutions in Tromsø

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.